Hypertension in patients with psoriasis and psoriatic arthritis
https://doi.org/10.18705/1607-419X-2022-28-1-6-16
Abstract
The article presents data on the features of hypertension (HTN) and the risk factors for its development in patients with psoriasis (PsO) and psoriatic arthritis (PsA). PsO and PsA are often accompanied by cardiovascular diseases which are associated with both chronic systemic Th1-Th17-mediated inflammation and metabolic changes in this group of patients. Currently, data show high rates of HTN in PsO, however, the pathophysiological relationship of these pathologies has not been fully determined. HTN development in PsO and PsA is mediated by many factors. Firstly, metabolism disorders including hyperuricemia, hyperglycemia, dyslipidemia can play a role. Moreover, PsO and PsA often cause stress and depression predisposing to smoking, alcohol consumption, hypodynamia, which are modifiable cardiovascular risk factors. Also, the medications for skin lesions and joint inflammation can lead to high blood pressure. In conclusion, there is no reason to avoid the use of certain antihypertensive drugs in PsO and PsA. Cardiovascular pathology significantly affects the quality of life, social adaptation, and the treatment opportunities of PsO and PsA.
About the Authors
A. N. Shishkin
St. Petersburg State University
Russian Federation
Russian Federation
Alexander N. Shishkin, MD, PhD, DSc, Professor, Head, Department of Faculty Therapy, Medical Faculty
8a 27 line V.O., St Petersburg, 199106
A. A. Nikolaeva
St. Petersburg State University
Russian Federation
Russian Federation
Alina A. Nikolaeva, MD, Postgraduate Student, Department of Faculty Therapy, Medical Faculty
8a 27 line V.O., St Petersburg, 199106
References
1. Agafonova EM, Klyukvina NG, Urumova MM. Coexistence of systemic lupus erythematosus and psoriatic arthritis: literature data and case description. Modern rheumatology. 2018;12(4):123–128. doi:10.14412/1996-7012-2018-4-123-128. In Russian.
2. Barilo AA, Smirnova SV, Smolnikova MV. Immunity parameters in patients with psoriatic arthritis depending on age. Medical immunology (Russia). 2019;21(1):69–76. doi:10.15789/1563-0625-2019-1-69-76. In Russian.
3. Torshina IE, Zirchik AA, Gelt TD. Significance of onychodystrophy in predicting cardiovascular diseases in patients with psoriasis. Difficult patient. 2017;15(6–7):28–30. In Russian.
4. Panshina NN, Shilova LN. Clinical features of the metabolic syndrome in patients with psoriatic arthritis. Volgograd Scientific Medical Journal. 2017:31–33. In Russian.
5. Favarato MH, Mease P, Gonçalves CR, Goncalves SC, Sampaio-Barros PD, Goldenstein-Schainberg C. Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis. Clin Exp Rheumatol. 2014;32(2):182–187.
6. Almodоvar R, Zarco P, Otоn T, Carmona L. Effect of weight loss on activity in psoriatic arthritis: a systematic review. Reumatol Clin. 2018;14(4):207–210. doi:10.1016/j.reuma.2017.01.010
7. Klingberg E, Bilberg A, Björkman S, Hedberg M, JacobssonL, Forsblad-d’Elia H. et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther. 2019;21(1):17. doi:10.1186/s13075-019-1810-5
8. Kavanaugh A, Helliwell P, Ritchlin C. Psoriatic arthritis and burden of disease: patient perspectives from the populationbased multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91–102. doi:10.1007/s40744-016-0029-z
9. Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken). 2011;63:195–202. doi:10.1002/acr.20363
10. Batkaeva NV, Batkaev EA, Gitinova MM, Malyarenko EN, Golovinov AI. Features of cardiovascular diseases in patients with severe and moderate forms of psoriasis. Bulletin of RUDN University. Series: Medicine. 2018;22(1):92–99. doi:10.22363/2313-0245-2018-22-1-92-101. In Russian.
11. Krüger K. Therapie kardiovaskulärer risikofaktoren [Treatment of cardiovascular risk factors]. Z Rheumatol. 2016; 75(2):173–180; quiz 181–182. German. doi:10.1007/s00393-016-0064-8. [Erratum in: Z Rheumatol. 2016 Jun;75(5):489].
12. Polachek A, Touma Z, Anderson M, Eder L. Risk of cardiovascular morbidity in patients with psoriatic arthritis: A meta-analysis of observational studies. Arthritis Care Res. 2017; 69(1):67–74. doi:10.1002/acr.22926
13. Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, Gladman DD. Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. Arthritis Care Res. (Hoboken). 2011;63:1729–1735. doi:10.1002/acr.20627
14. Pietrzak A, Bartosinska J, Blaszczyk R, Chodorowska G, Brzozowski W, Hercogova J et al. Increased serum level of N-terminal pro-B-type natriuretic peptide as a possible biomarker of cardiovascular risk in psoriatic patients. J. Eur. Acad. Dermatol. Venereol. 2015;29:1010–1014. doi:10.1111/jdv.12528
15. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The “psoriatic march”: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–307. doi:10.1111/j.1600-0625.2011.01261.x
16. Eiris N, Santos-Juanes J, Coto-Segura P, Gomez J, Alvarez V, Morales B et al. Resequencing of the IL12B gene in psoriasis patients with the rs6887695/ rs3212227 risk genotypes. Cytokine. 2012;60:27–29. doi:10.1016/j.cyto.2012.05.030
17. Naik HB, Natarajan B, Stansky E, Ahlman MA, Teague H, Salahuddin T et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. Arter. Thromb. Vasc. Biol. 2015;35:2667–2676. doi:10.1161/ATVBAHA.115.306460
18. Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbasi MO, Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br.J. Dermatol. 2008;159:820–826. doi:10.1111/j.1365-2133.2008.08742.x
19. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011;11:85. doi:10.1038/nri2921
20. Queiroz M, Sena CM. Perivascular adipose tissue in age-related vascular disease. Ageing Res. Rev. 2020;59:101040. doi:10.1016/j.arr.2020.101040
21. Quillard T, Araujo HA, Franck G, Shvartz E, Sukhova G, Libby P. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: Implications for superficial erosion. Eur. Heart J. 2015;36:1394–1404. doi:10.1093/eurheartj/ehv044
22. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, TroxelAB. Risk of myocardial infarction in patients with psoriasis. JAMA Dermatol. 2006;296:1735–1741. doi:10.1001/jama.296.14.1735
23. Duan X, Junbo L, Yunzhu M, Ting L, Yujuan C, Ruichao Yu et al. A systematic review and meta-analysis of the association between psoriasis and hypertension with adjustment for covariates. Medicine (Baltimore). 2020;99(9):e19303. doi:10.1097/MD.0000000000019303
24. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study.Acta Derm Venereol. 2010; 90(1):23–26. doi:10.2340/00015555-0741
25. Augustin M, Reich K, Glaeske G, Schaefer I, RadtkeM. Comorbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147– 151. doi:10.2340/00015555-0770
26. Armstrong AW, Caitlin HT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and metaanalysis of observational studies. J Hypertens. 2013;31(3):433–443. doi:10.1097/HJH.0b013e32835bcce1
27. Shrivastava AK, Singh HV, Raizada A, Singh SK. C-reactive protein, inflammation and coronary heart disease. Egypt Heart J 2015;67:89–97. doi.org/10.1016/j.ehj.2014.11.005
28. Staniak HL, Bittencourt MS, de Souza Santos I. Association between psoriasis and coronary calcium score. Atherosclerosis 2014;237:847–852. doi:10.1016/j.atherosclerosis.2014.11.004
29. Conic R, Damiani G, Schrom KP, Ramser AE, Zheng C, Xu R et al. Psoriasis and psoriatic arthritis cardiovascular disease endotypes identified by red blood cell distribution width and mean platelet volume. J Clin Med. 2020;9(1):186. doi:10.3390/jcm9010186
30. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction andother vascular diseases in patients with psoriasis. British Journal of Dermatology. 2008;159:895–902. doi:10.1111/j.1365-2133.2008.08707.x
31. Ma C, Harskamp CT, Armstrong EJ, Armstrong AW. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol. 2013;168(3):486–495. doi:10.1111/bjd.12101
32. Rebrov AP, Gaidukova IZ. Features of dyslipidemia in psoriatic arthritis: relationship with atherosclerosis, cardiovascular risk factors and systemic inflammation. Saratov Scientific Medical Journal. 2010;6(3):592–596 In Russian.
33. Jones SM, Harris CPD, Lloyd J, Stirling CA, Reckless JP, McHugh NJ. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann. Rheum.Dis. 2000;59(11):904–909. doi:10.1136/ard.59.11.904
34. Alenius GM, Jidell E, Nordmark L. Clinical data and lipids in psoriatic arthritis. J. Rheumatol.1998;25(54):39.
35. Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum. 2007;36(4):203–209. doi:10.1016/j.semarthrit.2006.09.001
36. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007;57(6):1074–1080. doi:10.1002/art.22884
37. Eder L, Jayakar J, Shanmugarajah S, Thavaneswaran A, Pereira D, Chandran V et al. The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann. Rheum. Dis. 2013;72:715–720. doi:10.1136/annrheumdis‑2012-201497
38. Khan A, Haider I, Ayub M, Humayun M. Psoriatic arthritis is an indicator of significant renal damage in patients with psoriasis: an observational and epidemiological study. Int J Inflam. 2017;2017:5217687. doi:10.1155/2017/5217687
39. Chikhladze NM, Chazova IE. Arterial hypertension and kidneys. Consilium Medicum 2015;17(10):8–12 In Russian.
40. Chazova IE, Zhernakova JuV, Kislyak OA, Nedogoda SV, Podzolkov EI, Oshchepkova EV et al. Consensus on the management of patients with hyperuricemia and high cardiovascular vascular risk. Systemic hypertension. 2019;16(4):8–21. doi:10.26442/2075082X.2019.4.190686. In Russian.
41. AlJohani R, Polachek A, Ye JYe, Chandran V, Gladman DD. Characteristic and outcome of psoriatic arthritis patients with hyperuricemia. J Rheumatol. 2018;45(2):213–217. doi:10.3899/jrheum.170384
42. Gui XY, Jin HZ, Wang ZJ, Xu TD. Serum uric acid levels and hyperuricemia in patients with psoriasis: a hospital-based cross-sectional study. An Bras Dermatol. 2018;93(5):761–763. doi:10.1590/abd1806-4841.20187547
43. Yilmaz E, Tamer E, Artuz F, Cakmak SK, Kokturk F. Evaluation of serum uric acid levels in psoriasis vulgaris. Turk J Med Sci. 2017;47(2):531–534. doi:10.3906/sag‑1512-5
44. Felten R, Duret P-R, Gottenberg J-E, Spielmann L, Messer L. At the crossroads of gout and psoriatic arthritis: “psout”. Review Clin Rheumatol.2020; 39(5):1405-1413. doi:10.1007/s10067-020-04981-0
45. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS et al. Psoriasis and comorbid diseases. Implications for management. J Am Acad Dermatol. 2017;76(3):393–403. doi:10.1016/j.jaad.2016.07.065
46. Zhao Q, Hong D, Zhang Y, Sang Y, Yang Z, Zhang X. Association between anti-TNF therapy for rheumatoid arthritis and hypertension: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2015;94(14):e731. doi:10.1097/MD.0000000000000731
47. Grossman C, Bornstein G, Leibowitz A, Ben-Zvi I, Grossman E. Effect of tumor necrosis factor-α inhibitors on ambulatory 24-h blood pressure. Blood Press. 2017;26(1):24–29. doi:10.1080/08037051.2016.1183460
48. Sandoo A, Panoulas VF, Toms TE, Smith JP, StavropoulosKalinoglou A, Metsios GS et al. Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis. J Hum Hypertens. 2011;25(11):699–702. doi:10.1038/jhh.2011.36
49. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):149–218. doi:10.15829/1560-4071-2020-3-3786. In Russian.
50. Fragoulis GE, Evangelatos G, Tentolouris N, Fragkiadaki K, Panopoulos S, Konstantonis G et al. Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. Ther Adv Musculoskelet Dis. 2020;12:1759720X20976975. doi:10.1177/1759720X20976975
51. Cardiovascular prevention 2017. Russian national guidelines. Russian journal of cardiology. 2018;23(6):7–122. doi:10.15829/1560-4071-2018-6-7-122. In Russian.
52. Katsimbri P, Korakas E, Kountouri A, Ikonomidis I, Tsougos E, Vlachos D et al. The effect of antioxidant and antiinflammatory capacity of diet on psoriasis and psoriatic arthritis phenotype: nutrition as therapeutic tool? Antioxidants (Basel). 2021;10(2):157. doi:10.3390/antiox10020157
53. Caso F, Navarini L, Carubbi F, Picchianti-Diamanti A, Chimenti MS, Tasso M et al. Mediterranean diet and psoriatic arthritis activity: a multicenter cross-sectional study. Rheumatol Int. 2020;40(6):951–958. doi:10.1007/s00296-019-04458-7
54. Weijers JM, Müskens WD, van Riel PLCM. Effect of significant weight loss on disease activity: reason to implement this non-pharmaceutical intervention in daily clinical practice. RMD Open. 2021;7(1):e001498. doi:10.1136/rmdopen‑2020–001498
55. Mulder MLM, Wenink MH, Vriezekolk JE. Being overweight is associated with not reaching low disease activity in women but not men with psoriatic arthritis. Rheumatology (Oxford). 2021; keab338. doi: 10.1093/rheumatology/keab338
56. Valero-Jaimes JA, López-González R, MartínMartínez MA, García-Gómez C, Sánchez-Alonso F, Sánchez-Costa JT et al. Body mass index and disease activity in chronic inflammatory rheumatic diseases: results of the cardiovascular in rheumatology (Carma) project. J Clin Med. 2021;10(3):382. doi:10.3390/jcm10030382
57. Perrotta FM, Scriffignano S, Benfaremo D, Ronga M, Luchetti MM, Lubrano E. New insights in physical therapy and rehabilitation in psoriatic arthritis: a review. Rheumatol Ther. 2021. doi:10.1007/s40744-021-00298-9
58. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5– 32. doi:10.1002/art.40726
59. Thomsen RS, Nilsen TIL, Haugeberg G, Gulati AM, Kavanaugh A, Hoff M. Adiposity and physical activity as risk factors for developing psoriatic arthritis: Longitudinal Data From a Population-Based Study in Norway. Arthritis Care & Research. 2021;73(3): 432–441. doi:10.1002/acr.24121
60. Green A, Shaddick G, Charlton R, Snowball J, Nightingale A, Smith C et al. Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. Br J Dermatol. 2020;182(3):714–720. doi:10.1111/bjd.18227
61. Gazel U, Ayan G, Solmaz D, Akar S, Aydin SZ. The impact of smoking on prevalence of psoriasis and psoriatic arthritis. Rheumatology (Oxford). 2020;59(10):2695–2710. doi:10.1093/rheumatology/keaa179
62. Nguyen USDT, Zhang Y, Lu N, Louie-Gao Q, Niu J, Ogdie A et al. Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. Ann Rheum Dis. 2018;77(1):119–123. doi:10.1136/annrheumdis‑2017-211625
63. Pezzolo E, Naldi L. The relationship between smoking, psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2019;15(1):41–48. doi:10.1080/1744666X.2019.1543591
64. Torre-Alonso JC, Carmona L, Moreno M, Galíndez E, Babío J, Zarco P et al. Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain. Rheumatol Int. 2017;37(8):1239–1248. doi:10.1007/s00296-017-3702-9
65. Smith MP, Ly K, Thibodeaux Q, Weerasinghe T, Beck K, Shankle L et al. Factors influencing sleep difficulty and sleep quantity in the citizen pscientist psoriatic cohort. Dermatol Ther (Heidelb). 2019;9(3):511–523. doi:10.1007/s13555-019-0306-1
66. Yilmaz MB, Turhan H, Akin Y, Kisacik HL, Korkmaz S. Beta-blocker-induced psoriasis: A rare side effect — a case report. Angiology. 2002;53:737–739. doi:10.1177/000331970205300617
67. O’Brien M, Koo J. The mechanism of lithium and betablocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol. 2006;5:426–432.
68. Loftus TJ, Efron PA, Moldawer LL, Mohr AM. β-blockade use for traumatic injuries and immunomodulation: A review of proposed mechanisms and clinical evidence. Shock. 2016;46:341– 351. doi: 10.1097/SHK.0000000000000636
69. Tatu AL, Elisei AM, Chioncel V, Miulescu M, Nwabudike LC. Immunologic adverse reactions of β-blockers and the skin (Review). Exp Ther Med. 2019;18(2):955–959. doi:10.3892/etm.2019.7504
70. Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol. 2010;3:32–38.
71. Shaw SM, Coppinger T, Waywell C, Dunne L, Archer LD, Critchley WR et al. The effect of beta-blockers on the adaptive immune system in chronic heart failure. Cardiovasc Ther. 2009;27:181–186. doi:10.1111/j.1755–5922.2009.00089.x
72. Wu S, Han J, Li WQ, Qureshi AA. Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol. 2014;150(9):957–963. doi:10.1001/jamadermatol.2013.9957
73. ShishkinAN, Nikolaeva AA, Smirnova IO. Psoriatic arthritis: current state of the problem. Bulletin of St. Petersburg University. Medicine. 2019;14(3):194–203. doi:10.21638/spbu11.2019.302. In Russian
Review
For citations:
Shishkin A.N., Nikolaeva A.A. Hypertension in patients with psoriasis and psoriatic arthritis. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2022;28(1):6-16. (In Russ.) https://doi.org/10.18705/1607-419X-2022-28-1-6-16
Views: 1481
Email this article 